FI954404A0 - Fenoksifenyylietikkahappojohdannaiset - Google Patents

Fenoksifenyylietikkahappojohdannaiset

Info

Publication number
FI954404A0
FI954404A0 FI954404A FI954404A FI954404A0 FI 954404 A0 FI954404 A0 FI 954404A0 FI 954404 A FI954404 A FI 954404A FI 954404 A FI954404 A FI 954404A FI 954404 A0 FI954404 A0 FI 954404A0
Authority
FI
Finland
Prior art keywords
vasospasm
cerebral
asthma
hypertension
chem
Prior art date
Application number
FI954404A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI954404A (fi
Inventor
Scott W Bagley
Theodore P Broten
Prasun K Chakravarty
Daljit S Dhanoa
Kenneth J Fitch
William J Greenlee
Nancy Jo Kevin
Douglas J Pettibone
Ralph A Rivero
James R Tata
Thomas F Walsh
Jr David L Williams
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of FI954404A0 publication Critical patent/FI954404A0/fi
Publication of FI954404A publication Critical patent/FI954404A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
FI954404A 1993-03-19 1995-09-18 Fenoksifenyylietikkahappojohdannaiset FI954404A (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3445593A 1993-03-19 1993-03-19
US19746794A 1994-02-24 1994-02-24
PCT/US1994/002871 WO1994021590A1 (en) 1993-03-19 1994-03-17 Phenoxyphenylacetic acid derivatives

Publications (2)

Publication Number Publication Date
FI954404A0 true FI954404A0 (fi) 1995-09-18
FI954404A FI954404A (fi) 1995-09-18

Family

ID=26710968

Family Applications (1)

Application Number Title Priority Date Filing Date
FI954404A FI954404A (fi) 1993-03-19 1995-09-18 Fenoksifenyylietikkahappojohdannaiset

Country Status (23)

Country Link
EP (1) EP0617001B1 (es)
JP (1) JPH08508034A (es)
KR (1) KR960700992A (es)
CN (1) CN1119434A (es)
AT (1) ATE189217T1 (es)
AU (1) AU679710B2 (es)
CA (1) CA2119051A1 (es)
CZ (1) CZ233595A3 (es)
DE (1) DE69422742T2 (es)
DK (1) DK0617001T3 (es)
ES (1) ES2141197T3 (es)
FI (1) FI954404A (es)
GR (1) GR3032643T3 (es)
HR (1) HRP940179B1 (es)
HU (1) HU217028B (es)
IL (1) IL108944A0 (es)
NO (1) NO953672L (es)
NZ (1) NZ263414A (es)
PL (1) PL175786B1 (es)
PT (1) PT617001E (es)
RU (1) RU2139273C1 (es)
SK (1) SK114795A3 (es)
WO (1) WO1994021590A1 (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124343A (en) * 1919-01-27 2000-09-26 Rhone-Poulenc Rorer Limited Substituted phenyl compounds with a substituent having a thienyl ring
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
WO1996004905A1 (en) * 1994-08-08 1996-02-22 Merck & Co., Inc. Phenoxyphenylacetic acid derivatives
US5686478A (en) * 1993-07-20 1997-11-11 Merck & Co. Inc. Endothelin antagonists
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5559135A (en) * 1994-09-14 1996-09-24 Merck & Co., Inc. Endothelin antagonists bearing pyridyl amides
US5538991A (en) * 1994-09-14 1996-07-23 Merck & Co., Inc. Endothelin antagonists bearing 5-membered heterocyclic amides
BR9606961A (pt) * 1995-01-27 1997-11-04 Rhone Poulenc Rorer Ltd Composto processo para a sua preparação composição farmacêutica método par tratar um estado doentio capaz de ser amenizado pela administração de um inibidor de endotelina e aplicação do composto
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
DE19527568A1 (de) * 1995-07-28 1997-01-30 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
DE19528418A1 (de) * 1995-08-02 1997-02-06 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
DE19530032A1 (de) * 1995-08-16 1997-02-20 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
DE19537548A1 (de) * 1995-10-09 1997-04-10 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
JPH09124620A (ja) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
US5688974A (en) * 1995-12-12 1997-11-18 Merck & Co., Inc. Process for the preparation of an endothelin antagonist
WO1997021700A1 (en) * 1995-12-12 1997-06-19 Merck & Co., Inc. Process for the preparation of an endothelin antagonist
US5977117A (en) * 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US5847008A (en) * 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
US6020382A (en) * 1996-02-02 2000-02-01 Merck & Co., Inc. Method of treating diabetes and related disease states
US5859051A (en) * 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
US6090836A (en) * 1996-02-02 2000-07-18 Merck & Co., Inc. Benzisoxazole-derived antidiabetic compounds
ATE293963T1 (de) * 1996-02-02 2005-05-15 Merck & Co Inc Verfahren zur behandlung von diabetes und verwandter krankheitszustände.
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
SG87053A1 (en) 1996-02-20 2002-03-19 Bristol Myers Squibb Co High melt polymorth of the compound n-(3,4-dimethyl-5-isoxazolyl)-4'- (2-oxazolyl) [1,1'-biphenyl]-2-sulfonamide
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
GB9609641D0 (en) * 1996-05-09 1996-07-10 Pfizer Ltd Compounds useful in therapy
DE19653024A1 (de) * 1996-12-19 1998-06-25 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
US6160000A (en) * 1996-12-23 2000-12-12 Merck & Co., Inc. Antidiabetic agents based on aryl and heteroarylacetic acids
US6090839A (en) * 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
WO1998033781A1 (en) * 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
DE19710831A1 (de) * 1997-03-15 1998-09-17 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
EP1014989B1 (de) * 1997-09-26 2004-01-14 Abbott GmbH & Co. KG Endothelin antagonist und renin-angiotensin system hemmer als kombinationspräparate
DE19743143A1 (de) * 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
GB9722287D0 (en) * 1997-10-22 1997-12-17 Pfizer Ltd Compounds useful in therapy
DE19747788A1 (de) 1997-10-29 1999-05-06 Basf Ag Substituierte 2-(2'-Pyridyloxy)phenylessigsäureamide, ihre Herstellung und Verwendung, sowie sie enthaltende Mittel
WO1999048530A1 (en) * 1998-03-23 1999-09-30 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
US6410554B1 (en) 1998-03-23 2002-06-25 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
NZ506877A (en) * 1998-03-31 2002-04-26 Tanabe Seiyaku Co Benzenesulfonamide compounds useful in treating dysuria
US6017918A (en) * 1998-08-06 2000-01-25 Warner-Lambert Company Phenyl glycine compounds and methods of treating atherosclerosis and restenosis
US6284795B1 (en) * 1998-09-04 2001-09-04 Warner-Lambert Company Sulfonamide compounds and methods of treating atherosclerosis and restenosis
AU3718900A (en) 1999-03-19 2000-10-09 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
AU1073001A (en) * 1999-10-12 2001-04-23 Basf Aktiengesellschaft Method of identifying inhibitors of cdc25
DE60144284D1 (de) 2000-11-01 2011-05-05 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
JP2004521124A (ja) 2001-02-09 2004-07-15 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病および脂質障害用の２−アリールオキシ−２−アリールアルカン酸類
CA2479338A1 (en) * 2002-03-20 2003-10-02 Metabolex, Inc. Substituted phenylacetic acids
US8614236B2 (en) 2006-12-12 2013-12-24 University Of Washington Methods of treating pulmonary disease using acetazolamide and structurally related derivatives
CN101042381B (zh) * 2007-04-28 2014-01-08 长春迈灵生物工程有限公司 一种地舍平的检测方法
JP2013510145A (ja) * 2009-11-09 2013-03-21 メディヴィル・アクチエボラーグ １，３−オキサゾリジン化合物およびレニン阻害剤としてのそれらの使用方法
CA2804593C (en) 2010-07-09 2015-11-24 Pfizer Limited Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors
WO2012007868A2 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
ES2525581T3 (es) 2010-07-12 2014-12-26 Pfizer Limited Derivados de N-sulfonilbenzamida útiles como inhibidores del canal de sodio dependiente de voltaje
JP2013532186A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物
CA2804877A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
WO2012007869A2 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
AU2011346670B2 (en) 2010-12-23 2015-05-07 Pfizer Inc. Glucagon receptor modulators
EA023517B1 (ru) 2011-02-08 2016-06-30 Пфайзер Инк. Модуляторы глюкагонового рецептора
CN103732578B (zh) 2011-07-22 2015-08-12 辉瑞大药厂 喹啉基胰高血糖素受体调节剂
WO2013088315A1 (en) 2011-12-15 2013-06-20 Pfizer Limited Sulfonamide derivatives
CN111825564B (zh) * 2020-09-21 2020-12-29 西藏甘露藏药股份有限公司 一种从渣驯中提取的化合物、制备方法及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1408738A (fr) * 1964-04-29 1965-08-20 Nobel Bozel Nouveaux dérivés de l'acide bis(hydroxy-4-phényl)-acétique
US4748272A (en) * 1986-08-01 1988-05-31 Rorer Pharmaceutical Corp. Phenoxyphenylacetates for use as potential modulators of arichidonic acid pathways
JPS63122605A (ja) * 1986-11-10 1988-05-26 Tokuyama Soda Co Ltd 除草剤組成物

Also Published As

Publication number Publication date
WO1994021590A1 (en) 1994-09-29
PT617001E (pt) 2000-06-30
IL108944A0 (en) 1994-06-24
HU217028B (hu) 1999-11-29
HRP940179B1 (en) 2000-10-31
NO953672D0 (no) 1995-09-18
NO953672L (no) 1995-11-17
HRP940179A2 (en) 1998-02-28
ATE189217T1 (de) 2000-02-15
DK0617001T3 (da) 2000-04-17
AU5787894A (en) 1994-09-22
CN1119434A (zh) 1996-03-27
EP0617001B1 (en) 2000-01-26
RU2139273C1 (ru) 1999-10-10
CA2119051A1 (en) 1994-09-20
CZ233595A3 (en) 1996-01-17
DE69422742T2 (de) 2000-08-17
KR960700992A (ko) 1996-02-24
GR3032643T3 (en) 2000-06-30
NZ263414A (en) 1997-09-22
AU679710B2 (en) 1997-07-10
ES2141197T3 (es) 2000-03-16
DE69422742D1 (de) 2000-03-02
JPH08508034A (ja) 1996-08-27
SK114795A3 (en) 1996-06-05
PL175786B1 (pl) 1999-02-26
HU9502725D0 (en) 1995-11-28
HUT73658A (en) 1996-09-30
PL310661A1 (en) 1995-12-27
EP0617001A1 (en) 1994-09-28
FI954404A (fi) 1995-09-18

Similar Documents

Publication Publication Date Title
NO953672L (no) Fenoksyfenyleddiksyrederivater
NO986090L (no) Fenylalaninderivater som integrininhibitorer
EA199800478A1 (ru) N-([1,2,4]триазолазинил)бензолсульфонамиды и пиридинсульфонамиды и их применение в качестве гербицидов
DE69435198D1 (de) "hedgehog-like" proteine von wirbeltieren, die embryonale strukturen induzieren
CA2297911A1 (en) Substituted 6-phenylphenanthridines
ATE323088T1 (de) Bicyclische pyridin-und pyrimidinderivate als neuropeptid y rezeptorantagonisten
AP9701004A0 (en) Low molecular weight bicyclic thrombin inhibitors.
CY1105091T1 (el) Αντικατεστημενες ενωσεις 2-αρυλοβενζαζολιου και η χρηση τους σαν παραγοντες κατα των ογκων
DE69908648D1 (de) Kondensierte 1,2,4-thiadiazinderivate, ihre herstellung und verwendung
HK1003031A1 (en) Condensed pyrimidine derivatives and their use as angiotensine ii antagonists
PT1023267E (pt) Compostos de piridilo e composicoes farmaceuticas que os contem
ATE179173T1 (de) 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy 1,3-propandiol-derivate
WO2000071516A3 (en) INHIBITORS OF FACTOR Xa
DE60203623D1 (de) Substituierte piperazinderivate und ihre verwendung als fettsaüreoxidationsinhibitoren
EE03564B1 (et) Bensotiasiindioksiidid kui endoteliini antagonistid
MX9202191A (es) Antagonistas de endotelina.
ES2186734T3 (es) Quinazolinas como inhibidores de la enzima de conversion de la endotelina.
DK478585D0 (da) 4-alkoxy-pyrido(2,3-d)pyrimidin-derivater, deres fremstilling og anvendelse
AR012094A1 (es) Derivados de quinolein-2(1h)-ona y de dihidroquinolein-2(1h)-ona, su preparacion y su aplicacion en terapeutica.
ATE86983T1 (de) Acyl-derivate von hydroxy-pyrimidinen.
EA200100151A1 (ru) Производные пиперазинона и их применение
MX12192A (es) Composicion farmaceutica para reducir o impedir las arritmias
TH49639EX (th) ข้อต่อไม้คิวสนุกเกอร์
RU92016440A (ru) Производные гидрокси- и алкоксипиридинов
IT221319Z2 (it) Mensola multiuso di tipo perfezionato.